Avalyn Pharma Raises $175M In Series C Financing Round

By Renee Hickman · September 27, 2023, 5:55 PM EDT

Clinical stage biopharmaceutical company Avalyn said on Wednesday that it had closed its Series C financing round after securing $175 million from a group co-led by Perceptive Xontogeny Venture Funds, SR...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Renee

February 14, 2024
Adagio Medical Goes Public In $128M SPAC Merger
February 12, 2024
Assure Buys Danam Health To Form $150M Business
February 06, 2024
McDermott-Led 3 Boomerang Nabs $375M For Debut Fund
September 14, 2023
Abcam Founder Opposes Danaher Deal, Wants Board Gone
August 29, 2023
US Chamber Backs Amgen In FTC's $27.8B Merger Challenge
August 18, 2023
4 Firms Guide SPAC Deal For $300M Pregnancy Care Co. Nuvo
August 14, 2023
Life Sciences Biz Paying Up To $200M For CBD Drugmaker
August 07, 2023
Estia Health Gives Thumbs Up To AU$838M PE Takeover Bid
July 28, 2023
Tivity Appeals Nutrisystem Merger Investor Class Cert, Again
July 17, 2023
FTC Moves To Block IQVIA Deal Over Health Ad Concerns